Literature DB >> 18392750

Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia--a new metabolic disorder.

Karin Tuschl1, Philippa B Mills, Howard Parsons, Marian Malone, Darren Fowler, Maria Bitner-Glindzicz, Peter T Clayton.   

Abstract

We report a new constellation of clinical features consisting of hypermanganesaemia, liver cirrhosis, an extrapyramidal motor disorder and polycythaemia in a 12 year-old girl born to consanguineous parents. Blood manganese levels were >3000 nmol/L (normal range <320 nmol/L) and MRI revealed signal abnormalities of the basal ganglia consistent with manganese deposition. An older brother with the same phenotype died at 18 years, suggesting a potentially lethal, autosomal recessive disease. This disorder is probably caused by a defect of manganese metabolism with the accumulation of manganese in the liver and the basal ganglia similar to the copper accumulation in Wilson disease. In order to assess the genetic basis of this syndrome we investigated two candidate genes: ATP2C2 and ATP2A3 encoding the manganese-transporting calcium-ATPases, SPCA2 and SERCA3, respectively. Genotyping of the patient and the family for microsatellite markers surrounding ATP2C2 and ATP2A3 excluded these genes. The patient was found to be heterozygous for both gene loci. Despite the unknown pathophysiology, we were able to develop a successful treatment regime. Chelation therapy with disodium calcium edetate combined with iron supplementation is the treatment of choice, lowering blood manganese levels significantly and improving clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18392750     DOI: 10.1007/s10545-008-0813-1

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  43 in total

1.  Manganese exposure in foundry furnacemen and scrap recycling workers.

Authors:  F Lander; J Kristiansen; J M Lauritsen
Journal:  Int Arch Occup Environ Health       Date:  1999-11       Impact factor: 3.015

Review 2.  The Ca2+/Mn2+ pumps in the Golgi apparatus.

Authors:  Kurt Van Baelen; Leonard Dode; Jo Vanoevelen; Geert Callewaert; Humbert De Smedt; Ludwig Missiaen; Jan B Parys; Luc Raeymaekers; Frank Wuytack
Journal:  Biochim Biophys Acta       Date:  2004-12-06

3.  Functional expression in yeast of the human secretory pathway Ca(2+), Mn(2+)-ATPase defective in Hailey-Hailey disease.

Authors:  Van-Khue Ton; Debjani Mandal; Cordelia Vahadji; Rajini Rao
Journal:  J Biol Chem       Date:  2001-12-06       Impact factor: 5.157

4.  Adenosine 5'-triphosphate dependent fluxes of manganese and and hydrogen ions in sarcoplasmic reticulum vesicles.

Authors:  M Chiesi; G Inesi
Journal:  Biochemistry       Date:  1980-06-24       Impact factor: 3.162

Review 5.  The importance of glutamate, glycine, and gamma-aminobutyric acid transport and regulation in manganese, mercury and lead neurotoxicity.

Authors:  Vanessa A Fitsanakis; Michael Aschner
Journal:  Toxicol Appl Pharmacol       Date:  2005-05-01       Impact factor: 4.219

6.  Paraparesis, hypermanganesaemia, and polycythaemia: a novel presentation of cirrhosis.

Authors:  S M Gospe; R D Caruso; M S Clegg; C L Keen; N R Pimstone; J M Ducore; S S Gettner; R A Kreutzer
Journal:  Arch Dis Child       Date:  2000-11       Impact factor: 3.791

7.  Sequence variants of the sarco(endo)plasmic reticulum Ca(2+)-transport ATPase 3 gene (SERCA3) in Caucasian type II diabetic patients (UK Prospective Diabetes Study 48).

Authors:  A Varadi; L Lebel; Y Hashim; Z Mehta; S J Ashcroft; R Turner
Journal:  Diabetologia       Date:  1999-10       Impact factor: 10.122

Review 8.  Pathophysiology and clinical features of Wilson disease.

Authors:  Peter Ferenci
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

9.  Sequence variations in the first exon of alpha-galactosidase A.

Authors:  J P Davies; B G Winchester; S Malcolm
Journal:  J Med Genet       Date:  1993-08       Impact factor: 6.318

10.  Manganese inhalation by rhesus monkeys is associated with brain regional changes in biomarkers of neurotoxicity.

Authors:  Keith M Erikson; David C Dorman; Lawrence H Lash; Michael Aschner
Journal:  Toxicol Sci       Date:  2007-03-07       Impact factor: 4.849

View more
  45 in total

1.  Two-year follow-up after chelating therapy in a patient with adult-onset parkinsonism and hypermanganesaemia due to SLC30A10 mutations.

Authors:  L Di Toro Mammarella; A Mignarri; C Battisti; L Monti; V Bonifati; F Rasi; A Federico
Journal:  J Neurol       Date:  2013-11-26       Impact factor: 4.849

Review 2.  Manganese and its role in Parkinson's disease: from transport to neuropathology.

Authors:  Michael Aschner; Keith M Erikson; Elena Herrero Hernández; Elena Herrero Hernández; Ronald Tjalkens
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

3.  Small Molecule Modifiers of In Vitro Manganese Transport Alter Toxicity In Vivo.

Authors:  Tanara V Peres; Kyle J Horning; Julia Bornhorst; Tanja Schwerdtle; Aaron B Bowman; Michael Aschner
Journal:  Biol Trace Elem Res       Date:  2018-09-28       Impact factor: 3.738

4.  SLC30A10 is a cell surface-localized manganese efflux transporter, and parkinsonism-causing mutations block its intracellular trafficking and efflux activity.

Authors:  Dinorah Leyva-Illades; Pan Chen; Charles E Zogzas; Steven Hutchens; Jonathan M Mercado; Caleb D Swaim; Richard A Morrisett; Aaron B Bowman; Michael Aschner; Somshuvra Mukhopadhyay
Journal:  J Neurosci       Date:  2014-10-15       Impact factor: 6.167

Review 5.  Diagnosis of dystonic syndromes--a new eight-question approach.

Authors:  Kelly L Bertram; David R Williams
Journal:  Nat Rev Neurol       Date:  2012-03-20       Impact factor: 42.937

6.  SLC30A10: A novel manganese transporter.

Authors:  Pan Chen; Aaron B Bowman; Somshuvra Mukhopadhyay; Michael Aschner
Journal:  Worm       Date:  2015-05-11

7.  Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease.

Authors:  Marialuisa Quadri; Antonio Federico; Tianna Zhao; Guido J Breedveld; Carla Battisti; Cathérine Delnooz; Lies-Anne Severijnen; Lara Di Toro Mammarella; Andrea Mignarri; Lucia Monti; Antioco Sanna; Peng Lu; Francesca Punzo; Giovanni Cossu; Rob Willemsen; Fabrizio Rasi; Ben A Oostra; Bart P van de Warrenburg; Vincenzo Bonifati
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

8.  Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man.

Authors:  Karin Tuschl; Peter T Clayton; Sidney M Gospe; Shamshad Gulab; Shahnaz Ibrahim; Pratibha Singhi; Roosy Aulakh; Reinaldo T Ribeiro; Orlando G Barsottini; Maha S Zaki; Maria Luz Del Rosario; Sarah Dyack; Victoria Price; Andrea Rideout; Kevin Gordon; Ron A Wevers; W K Kling Chong; Philippa B Mills
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

9.  Hypothyroidism induced by loss of the manganese efflux transporter SLC30A10 may be explained by reduced thyroxine production.

Authors:  Chunyi Liu; Steven Hutchens; Thomas Jursa; William Shawlot; Elena V Polishchuk; Roman S Polishchuk; Beth K Dray; Andrea C Gore; Michael Aschner; Donald R Smith; Somshuvra Mukhopadhyay
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

10.  Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations.

Authors:  Margaret R DeWitt; Pan Chen; Michael Aschner
Journal:  Biochem Biophys Res Commun       Date:  2013-01-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.